Modelling approaches: The case of schizophrenia

PharmacoEconomics

Volumn 26, Issue 8, 2008, Pages 633-648

  Heeg, Bart M S ^a   Damen, Joep ^a   Buskens, Erik ^a   Caleo, Sue ^b   De Charro, Frank ^a   Van Hout, Ben A ^a  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Antipsychotics, therapeutic use; Cost effectiveness; Decision analysis; Discrete event simulation; Markov model; Modelling; Schizophrenia, treatment

Indexed keywords

CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; DECISION TREE; HEALTH ECONOMICS; NOTE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SCHIZOPHRENIA; SIMULATION;

COST-BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT TECHNIQUES; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; SCHIZOPHRENIA;

EID: 47249143377     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826080-00002     Document Type: Note

References (42)

1. Brennan A, Akehurst R. Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics 2000; 17: 445-59
2. Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217-27
3. Karnon J, Brown J. Selecting a decision model for economic evaluation: a case study and review. Health Care Manag Sci 1998; 1: 133-40
4. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004 Apr; 9 (2): 110-8
5. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006; 15: 1295-310
6. Glazer W, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 1996; 57: 337-45
7. Edwards N, Rupnow F, Pashos C, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics 2005; 23: 299-314
8. Palmer A, Revicki D, Genduso L, et al. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Manag Care 1998; 4: 345-55
9. Almond S, O'Donnel O. Cost analysis of the treatment of schizophrenia in the UK. A comparison of olanzapine and haloperidol. Pharmacoeconomics 1998; 13 (5): 575-88
10. Law A, Kelton D. Simulation modeling and analysis. 2nd ed. Singapore: McGraw-Hill, 1999
11. Heeg BMS, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005; 23 Suppl. 1: 17-33
12. Chue PS, Heeg BMS, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005; 23 Suppl. 1: 62-74
13. Laux G, Heeg BMS, van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005; 23 Suppl. 1: 49-61
14. De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 2005; 23 Suppl. 1: 35-47
15. Hunink M, Glasziou P. Decision making in health and medicine: integrating evidence and values. 3rd ed. Cambridge: The press syndicate of the University of Cambridge, 2004
16. Vera-Llonch M, Delea T, Richardson E, et al. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health 2004; 7: 569-84
17. Clewell J, Baker R. Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorder: a Markov model". Value Health 2005; 8: 175
18. Limpscomb J. Time preference for health in cost-effectiveness analysis. Med Care 1989; 27: S23-53
19. Oakley J, O'Hagan A. Probabilistic sensitivity analyses of complex models: a Bayesian approach. J R Statist Soc 2005; 3: 751-69
20. Karnon J. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Econ 2003; 12: 837-48
21. Habbema J, Lubbe J, van Oortmarssen GJ, et al. A simulation approach to cost-effectiveness and cost benefit calculations of screening for the early detection of disease. Eur J Operat Res 1987; 29: 159-66
22. van Hout BA, Bonsel G, Habbema D, et al. Heart transplantation in the Netherlands; costs, effects and scenarios. J Health Econ 1993; 12: 73-93
23. Caro J. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005; 23 (4): 323-32
24. Rubio G, Martinez I, Ponce G, et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006 Jul; 51 (8): 531-9
25. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003 Jun; 60 (6): 553-64
26. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162: 1-7
27. Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 2003; 7 (13): 1-193
28. Lieberman J, Stroup S, McEvoy P, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23
29. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000 Dec 2; 321: 1371-6
30. Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000; 15: 121-31
31. Revicki D, Genduso L, Hamilton S, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Quality Life Res 1999; 8: 417-21
32. Lindenmayer JP, Czobor P, Volavka JLJ. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry 2004; 4: 551-6
33. Turner MS, Stewart DW. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. J Psychopharmacol 2006 Nov; 20 (6 Suppl.): 20-37
34. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006 Oct; 63 (10): 1079-87
35. Mahmoud R, Engelhart L, Janagap C, et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. Clin Drug Invest 2004; 24: 275-86
36. Kane JM, Meltzer HY, Carson Jr WH, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007 Feb; 68 (2): 213-23
37. Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158: 266-9
38. Tunis S, Faries D, Nyhuis AW, et al. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 2006; 9 (5): 357
39. Lenert L, Sturley A, Rapaport M, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004; 71: 155-65
40. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices. Value Health 2003; 6: 9-17
41. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996 Oct 16; 276 (15): 1253-8
42. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000; 17: 461-77